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Identification and in silico analysis of GALNS mutations causing Morquio A syndrome
in eight consanguineous families
1

1

1

1

1

1

Irfan ULLAH , Abdul NASIR , Sarmad MEHMOOD , Sohail AHMED , Muhammad Ikram ULLAH , Asmat ULLAH ,
2
1
1
3
4
1,
Abdul AZIZ , Syed Irfan RAZA , Khadim SHAH , Saadullah KHAN , Muhammad Jawad HASSAN , Wasim AHMAD *
1
Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University Islamabad, Pakistan
2
Department of Computer Science & Bioinformatics, Khushal Khan Khattak University, Karak, KPK, Pakistan
3
Department of Biotechnology & Genetic Engineering, Kohat University of Science & Technology (KUST), Kohat, KPK, Pakistan
4
Atta ur Rahman School of Applied Biosciences, National University of Science & Technology (NUST), Islamabad, Pakistan
Received: 31.07.2016

Accepted/Published Online: 08.01.2017

Final Version: 14.06.2017

Abstract: Genetic deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS) due to mutations in the GALNS gene results in the
pathogenesis of Morquio A syndrome. To date, more than 200 mutations have been reported in GALNS, resulting in variable clinical
features. For this reason, bioinformatics analysis of these mutations is important to determine their effect on the structure and functions
of the protein and to establish a correlation between genotype and phenotype. In the present study, eight Pakistani consanguineous
families with Morquio A syndrome were clinically and genetically evaluated. Linkage analysis followed by sequence analysis of the
gene detected four novel (p.Phe216Ser, p.Met38Arg, p.Ala291Ser, p.Glu121Argfs*37) and two reported (p.Pro420Arg, p.Arg386Cys)
mutations in the eight families. In silico structural and functional analysis predicted that these mutations disrupt the function of GALNS
protein through fluctuating its three-dimensional structure, stability, and binding affinity and produce severe phenotypes. This is the
first comprehensive study on molecular analysis of patients with Morquio A syndrome from Pakistan that reports four novel mutations
with their structural and functional consequences.
Key words: Morquio A syndrome, GALNS, missense mutations, in silico analysis

1. Introduction
Genetic
deficiency
of
lysosomal
enzyme,
N-acetylgalactosamine-6-sulfate
sulfatase
(GALNS,
EC 3.1.6.4), due to mutations in the GALNS gene
[OMIM: 612222] leads to intralysosomal accumulation
of glycosaminoglycans (GAGs): chondroitin-6-sulfate
(C6S) and keratin sulfate (KS), which ultimately cause
mucopolysaccharidosis IV A [Morquio A disease (MIM:
253000)] (Harmatz et al., 2013; Yasuda et al., 2013). MPS
IV A is a lysosomal storage disease characterized by
systemic skeletal deformities including disproportionate
short stature with a short neck, pigeon chest, lumbar
kyphosis, genu valgum, broad mouth and prominent
maxilla in association with joint laxity, corneal clouding,
valvular heart defects, and pulmonary dysfunction
(Montaño et al., 2007a; Tomatsu et al., 2011; Harmatz et
al., 2013; Hendriksz et al., 2013).
Morquio A syndrome’s causative gene GALNS contains
14 exons spanning 35 kb on chromosome 16q24.3 and is
transcribed into 1566 base pairs cDNA that encodes 522
amino acids protein, a 60 kDa glycopeptide (Masue et al.,
* Correspondence: wahmad@qau.edu.pk
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1991; Masuno et al., 1993). Based on X-ray diffraction
analysis, Rivera-Colón et al. (2012) demonstrated that
GALNS is a homodimeric glycoprotein containing a
N-terminal domain (amino acids 28–379) enclosing the
active site, a second domain (amino acids 380–481), and a
C-terminal disc (amino acids 482–510), which twists back
toward domain 1 and delineates a portion of the active site.
Comprehensive analysis of the disease-causing mutations
reported in GALNS revealed that only 5% of mutations
occur in the active‐site residues, 65% in the buried residues
of the core protein, and 27% in surface residues (RiveraColón et al., 2012).
To date, more than 200 mutations have been reported
in the GALNS gene, which include 75% point mutations
(missense/nonsense), small deletions (10%), splice site
mutations (8%), small insertions (1.7%), small indel (1%),
gross deletions (1.7%), gross insertions/duplications (1%),
and complex rearrangements (1%) (Morrone et al., 2014a,
2014b; Stenson et al., 2014). In general, this mutational
heterogeneity leads to difficulties in the interpretation
of patient genotypes as many patients may carry novel
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or poorly characterized mutations. As a general rule,
the GALNS mutations have been categorized under four
groups: (i) those that demolish or alter the packaging of
hydrophobic core, (ii) those that eliminate the salt bridge
to disrupt the entire conformation, (iii) those changing
the active site geometry, or (iv) those that alter the surface
of the protein to change lysosomal targeting, hydrogen
bonds, or N-glycosylation sites (Sukegawa et al., 2000;
Montaño et al., 2007b). Some mutations, like nonsense
mutations, large deletions, and frameshifts, have solid
impact on GALNS protein activity but interpretation of
missense mutations is quite challenging (Tomatsu et al.,
2005; Hendriksz et al., 2013).
The three-dimensional (3D) structure of a protein
provides the framework for its dynamics and functions.
In silico modeling assists in structural and functional
elucidation of proteins to determine the effect of
mutations on the protein structure and thus its link with
disease because the function of a protein is critically
dependent on a well-defined conformation (Dunker et
al., 2002). For that reason, several bioinformatics tools
are employed for structural and functional analysis of
missense mutations in GALNS to determine their effect
on structural modifications, alterations in ligand binding
affinity, and the manifestations of a positive correlation
between mutations and severe phenotype (Sudhakar and
Mahalingam, 2011).

In the study presented here, eight Pakistani
consanguineous families with Morquio A syndrome were
evaluated at molecular level. Linkage in seven families (A,
B, C, D, E, F, G) was established to GALNS on chromosome
16q24.3. Subsequent Sanger sequencing of the GALNS
gene plus targeted next generation sequencing in family H
revealed four novel and two previously reported mutations
in the eight families. Additionally, in silico analysis was
carried out to predict the mechanistic consequences of
missense mutations. It was countersigned by in silico
analysis that these mutations have great impact on the
structure and function of the GALNS protein.
2. Materials and methods
2.1. Ethical approval and study subjects
Ethical approval to conduct this study was obtained from
the Institutional Review Board (IRB) of Quaid-i-Azam
University, Islamabad Pakistan. Mucopolysaccharidosis
type IVA/Morquio A syndrome was characterized both
clinically and genetically in eight consanguineous families
(A, B, C, D, E, F, G, H) of Pakistani origin (Figure 1). Four
families (A, B, C, F) were from Khyber Pakhtunkhwa
(KPK), two (D, H) from Punjab, one (E) from Baluchistan,
and family G was from Bajur Agency, FATA, Pakistan.
Blood samples were collected from 56 members
including four affected (IV-4, IV-5, IV-6, IV-7) and seven
unaffected individuals (III-1, III-2, III-3, III-4, IV-2, IV-3,

Figure 1. Pedigrees, demonstrating segregation of Morquio A syndrome in families A, B, D, E, F G, and H (a–h). Affected males
and females are shown by filled squares and circles, respectively. Symbols with bars indicate deceased individuals. Double lines
between individuals represent consanguineous union. The Roman numerals indicate the generation number of the individuals
within pedigree while Arabic numerals indicate their positions within a generation. The individual numbers labeled with
asterisks indicate the samples available for this study. Mutations identified in these families are mentioned with each individual
in line with their homozygous or heterozygous state.
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IV-8) in family A, three affected (IV-4, IV-5, IV-6) and four
unaffected individuals (III-1, III-2, IV-2, IV-3) in family B,
two affected (IV-2, IV-3) and four unaffected individuals
(III-1, III-2, IV-1, IV-4) in family C, one affected (V-1)
and six unaffected individuals (IV-3, IV-4, IV-5, IV-6,
V-2, V-4) in family D, two affected (IV-1, IV-2) and three
unaffected individuals (III-1, III-3, IV-3, IV-4) in family E,
two affected (IV-2, IV-3) and four unaffected individuals
(III-1, III-2, IV-1, IV-4) in family F, two affected (IV-3,
IV-4) and four unaffected individuals (III-2, III-3, IV-1,
IV-2) in family G, and two affected (IV-2, IV-3) and six
unaffected individuals (IV-5, IV-6, V-2, V-4, V-6, V-7) in
family H.
2.2. Extraction of genomic DNA and genotyping
Genomic DNA was extracted from the blood samples
using a Sigma GenElute Blood Genomic DNA kit (Sigma
Aldrich, St Louis, MO, USA). Based on clinical phenotypes,
DNA samples from affected and unaffected individuals
of the eight families (A, B, C, D, E, F, G, H) were tested
for linkage using microsatellite markers flanking GALNS
on chromosome 16q24.3. PCR was performed to check
linkage in these families as described previously (Irfanullah
et al., 2015). Linkage in seven families was established
to the GALNS gene using twelve microsatellite markers
(D16S498, D16S486, D16S3123, D16S3074, D16S3077,
D16S3063, D16S3123, D16S689, D16S2621, D16S3023,
D16S3026, D16S3121).
2.3. Targeted next generation sequencing
Family H was not linked to chromosome 16q24.3.
Therefore, it was submitted for next generation sequencing
at the Institute of Human Genetics, Jena University
Hospital, Jena, Germany. A DNA sample of one affected
member (V-5) was subjected to targeted resequencing
using an Illumina kit: Trusight one sequencing panel on
a NextSeq 500 platform that is designed for enrichment
and final analysis of a panel of coding regions of almost
5000 genes (www.illumina.com/products/trusight-onesequencing-panel.ilmn). The kit contained all the reagents
required for the amplification, amplicon enrichment,
indexing of the samples, and the use of NextSeq 500.
First of all, an indexed, pooled library was prepared from
genomic DNA using integrated barcodes according to
the manufacturer’s protocol. Then the targeted regions
were hybridized with biotinylated probes followed by
enrichment with streptavidin beads to prepare sequencing
ready fragments. Finally, the libraries were loaded to
a flow cell for sequencing using an Illumina NextSeq
500 instrument. Fastq files were aligned to the hg19
human reference sequence using the Burrows-Wheeler
Aligner (BWA) (Li et al., 2009). Variant detection and
calling were performed using the a Genome Analysis
Toolkit (GATK) (McKenna et al., 2010; DePristo et al.,
2011) to produce variant calling files (VCF). NextGene
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software (SoftGenetics LLC) was used for data processing,
alignment, variant calling, and annotation. Before variant
analysis and interpretation was started, intergenic and
frequent (with a frequency above 0.001 in single nucleotide
polymorphism database, dbSNP132 (ftp://ftp.ncbi.nlm.
nih.gov/snp/00readme.txt) or the 1000 Genomes Project
Database (www.1000genomes.org)) variants were excluded.
As a final point, the variants with average coverage >30x
and read quality >Q20 were filtered for missense, nonsense,
frameshift, and splice site mutations.
2.4. Sanger sequencing
All 14 exons of GALNS (MIM 253000) with adjacent
sequences of exon–intron borders were ampliﬁed by PCR
using gene-speciﬁc primers. Primers were designed by
means of the ‘Primer3’ program (Rozen and Skaletsky, 2000).
Puriﬁcation of the PCR-ampliﬁed products was performed
with a commercially available kit (Marligen Biosciences,
Ijamsville, MD, USA). The puriﬁed PCR products were
then sequenced with an ABI Prism310 Genetic Analyzer
(Applera, Foster City, CA, USA) using a Big Dye Terminator
v3.1 Cycle Sequencing Kit. BioEdit sequence alignment
tools (editor version 6.0.7, Ibis Biosciences, Carlsbad, CA,
USA) were used to detect pathogenic sequence variants in
the gene GALNS.
2.5. In silico structural and functional analysis
Bioinformatics analyses were carried out to investigate the
effects of mutations on protein structure and function. The
3D X-ray structure of human GALNS with the resolution
2.2 Å was retrieved from the protein databank (http://
www.rscb.org./pdb; code 4FDI), while the structure of
N-acetylgalactosamine-6-sulfate (GalNAc-6S, CID 193456)
(C6S, CID 24766) was retrieved from PubChem (RiveraColón et al., 2012). All the water molecules were removed
from the structure and hydrogen atoms were added. This
structure was then energy minimized with amber 99
force field in the MOE software packages (http://www.
chempcomp.com). Structures of the mutants were developed
by changing the selected residue into the desired residue
followed by refinement of the structures by subjecting to
a similar energy minimization protocol that was used for
the wild-type structure. Wild-type GALNS protein and its
mutants were superimposed and their root mean square
deviation (RMSD) and potential energy were calculated.
The molecular docking study was carried out against
6S-GalNAc as a substrate to predict the docking score and
binding pose of the ligand in the active site. Docking scores
were calculated on the basis of numbers of rotatable bonds
immobilized in ligand protein complex formation. A higher
docking score revealed a decrease in binding affinity of
the protein and vice versa. The predicted 3D structure of
the protein and docking pose were visualized by PyMOL
(http://pymol.org/, The PyMOL Molecular Graphics
System, version 1.3; Schrödinger, LLC).
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3. Results
3.1. Clinical features
Affected members in eight families (A–H) shared
phenotypic similarities with some differences (Table 1).
Clinical features of affected individuals included marked
skeletal deformities such as disproportionate short stature,
petite neck and trunk, pectus carinatum i.e. pigeon chest,
broad mouth, dental anomalies, valgus deformities of the
knees, and abnormal flexibility of joints. Kyphoscoliosis
i.e. combination of outward curvature (kyphosis) and
lateral curvature (scoliosis) of the spine, abnormal faces,
curved leg bones, and platyspondyly characterized by
flattened vertebral bodies throughout the axial skeleton
were observed in affected individuals (Figure 2). Affected
members in families A and B showed noteworthy short
stature with 4–5 SDS below normal with no associated
intellectual complications. Affected members of C and D
showed severe phenotypes of the syndrome. Two affected
members in family D died at the age of 13–15 years.
Patients in families E, F, and G were most severely affected;
they were unable to walk and had insightful intellectual
disability. A short life span was observed in affected
individuals of family H and four individuals died at the
age of 18–23.
3.2. Linkage analysis and mutation screening
Linkage in the families was tested using microsatellite
markers flanking the GALNS gene on chromosome
16q24.3. Except for family H, linkage in all the families
was established to GALNS. All 14 exons of the GASLNS,
including exon intron boundaries, were sequenced in
affected and unaffected members of the seven families.
Sequence analysis detected a homozygous missense
mutation (c.1259C > G; p.Pro420Arg) in exon 12 of
GALNS in affected members of families A and B (Figures
3a–3c). In family C, a missense mutation (c.1156C > T,
p.Arg386Cys) was found in exon 11 (Figures 3d–3f) while
affected members in family D showed another missense
mutation (c.647T > C; p.Phe216Ser) in exon 7 of the
gene (Figure 3g–3i). In three families (E, F, G) there was
a frameshift mutation, involving insertion of adenine
between nucleotide number 360 and 361 (c.360–361InsA;
p.Glu121Argfs*37) (Figure 3j–3l) that resulted in changing
the open reading frame of the protein after amino acid
number 120 with a premature stop codon 37 amino acids
ahead the frameshift.
A DNA sample of an affected member (V-5) from
family H, which failed to show linkage, was subjected
to targeted next generation sequencing using TruSight
One Sequencing Panel. Taking into consideration the
phenotypes observed in the family, a panel of genes was
piled up encompassing 18 genes, which have been reported
in literature to be associated with mucopolysaccharidosis
and related syndromes (Table 2). Downstream analysis

revealed two heterozygous missense mutations (c.114T
> G; c.871G > T: p.Met38Arg; p.Ala291Ser) in GALNS
whereas no pathogenic sequence variant was observed in
the rest of the 17 genes. Sanger sequencing showed that
affected individuals (V-3, V-5) were heterozygous for both
mutations alleles [c.114T > G; c.871G > T] in exons 1 and
8, respectively. On the other hand, only one heterozygous
variant (c.114T > G) was found in their mother and
(c.871G > T) in their father (Figure 3m–3r).
3.3. In silico structural and functional analysis
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), an
online tool, was used to analyze the impact of missense
mutations on the structure and functions of the protein.
It was revealed that all five mutations—P.Pro420Arg,
p.Arg386Cys, p.Phe216Ser, Ala291Ser, and Ala38Arg—
were probably damaging with a pathogenicity score of
0.709, 1.00, 0.984, 0.999, and 0.984, respectively. The
possible pathogenic impact of frameshift mutation (c.360361InsA; p.Glu121Argfs*37) was checked using Mutation
Taster (http://www.mutationtaster.org), which showed the
mutation is disease causing with a maximum probability
score of 1.00.
3.4. Effect of mutations on intermolecular interactions
and protein’s confirmation
The structure of the entire GALNS protein was developed
and labeled with missense mutations (P.Pro420Arg,
p.Arg386Cys, p.Phe216Ser, Ala291Ser, and Ala38Arg)
according to their positions in the protein (Figure 4A).
Using PyMOL software, the effect of mutations on
intermolecular interactions was evaluated. In the case
of p.Prro420Arg, a nonpolar amino acid (Proline420) is
replaced by a larger and more positively charged arginine.
As a result, a guanidium group is introduced in the loop
region to develop an intermolecular hydrogen bond
with side chain of Ala291 (Figures 4a and 4b), thereby
distorting the protein conformation. On the other hand,
with substitution of Arginine386 by cysteine in the case
of p.Arg386Cys, the intermolecular interaction between
Arg386 with Ala104 and Thr406 is lost, affecting the
protein folding (Figures 4c and 4d). In the case of the third
missense mutation (p.Phe216Ser), H-bonding among
Phe216, Val134, Phe226, and Leu228 is demolished. The
Ser216 developed new interactions with three residues
(Leu34, Val138, Ile217), which altered the 3D structure of
the protein (Figures 4e and 4f). Similarly, substitution of
methionine 38 by arginine (p.Met38Arg) resulted in loss
of the intermolecular interaction with Trp230, Val232, and
Phe285, distorting β sheet conformation (Figures 4g and
4h). Replacement of alanine 291 by serine (p. Ala291Ser)
resulted in generation of an additional interaction with
Gly301 in addition to its interaction with Cys308 and
Asn303 (Figures 4i and 4j).
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Table 1. Summary of clinical and mutational spectrum identified in the eight families.
Family

A

Consanguinity in
parents

B

C

D

E

F

G

H

1st cousins 1st cousins 1st cousins 1st cousins 1st cousins

1st cousins

1st cousins

1st cousins

Patients

4

3

2

1

2

2

2

2

Mutations

p.P420R

p.P420R

p.R386C

p.F216S

p.E121Rfs*37 p.E121Rfs*37 p.E121Rfs*37 p.M38R/p.A291S

Hom/Het

Hom

Hom

Hom

Hom

Hom

Hom

Hom

Comp. Het

Polyphen2

0.790

0.790

1.00

0.984

N/A

N/A

N/A

0.999/0.984

Mutation Taster

0.999

0.999

0.999

0.999

1.000

1.000

1.000

0.999/ 0.999

Effect on P.E.

+5.15

+5.15

–43.70

+627.17

N/A

N/A

N/A

–48.8/+16.09

Effect on L.B.

+7.020

+7.020

+2.255

+1.098

N/A

N/A

N/A

+3.148/+2.775

Age of disease onset

1–2 years

1–2 years

2 years

16 months

1 year

1 year

1 year

14 months

Height

70–82 cm

68–77 cm

90–94 cm

88 cm

106–112 cm

105–111 cm

102–110 cm

100–106 cm

Prognathism

_

_

_

_

+

+

+

_

Pectus carinatum

+

+

+

+

+

+

+

+

Kyphosis

+

+

N/A

+

N/A

N/A

N/A

+

Scoliosis

+

+

N/A

+

N/A

N/A

N/A

+

Platyspondyly

+

+

+

+

+

+

+

+

Coxa valga

+

+

N/A

+

N/A

N/A

N/A

+

Genu valgum

+

+

+

+

+

+

+

+

Flat feet

+

+

+

+

+

+

+

+

Joint laxity

+

+

+

+

+

+

+

+

Intellectual disability _

_

_

_

+

+

+

_

Corneal opacity

_

_

_

+

+

+

+

_

Widely spaced teeth

+

+

+

+

+

+

+

+

Clinical features

Patients (number of patients in family), Hom (Homozygous), Het (Heterozygous), P.E. (potential energy, + means increase and _ means
decrease in P.E.), L.B. (Ligand binding affinity, i.e. docking score. + and _ signs means increase or decrease in docking score), N/A (not
assessed)

3.5. Calculating potential energy
The stability of the protein was scrutinized by calculating
the difference between potential energy of wild-type
GALNS protein and its mutants (Table 1). The potential
energy value for wild-type GALNS protein was –1575.30
kcal/mol. A slight increase in potential energy was
noted for mutant p.Pro420Arg (–1570.45 kcal/mol) and
p.Ala291Ser (–1559.21 kcal/mol), whereas a significant
increase in potential energy was noted in the case of
p.Phe216Ser (–948.13 kcal/mol). On the other hand, in the
case of p.Met38Arg and p.Arg386Cys potential energy was
considerably decreased (–1624.10 kcal/mol and –1619.00
kcal/mol).
3.6. Molecular docking
To investigate the impact of the mutations on protein-ligand
binding, molecular docking of normal GALNS protein
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and all five mutants was carried out using N-Acetyl-Dgalactosamine 6-sulfate (GalNAc-6S) as a ligand. Finally,
a substantial difference in the docking score for normal
GALNS protein (–18.099) in contrast with its mutant
proteins including p.Pro420Arg (–11.079), p.Arg386Cys
(–15.844), p.Phe216Ser (–17.001), p.Met38Arg (–14.951),
and p.Ala291Ser (–15.324) was observed. The docking
score values demonstrated that normal GALNS has a
stronger binding pattern in the active site as compared to
its mutant forms (Figures 5a–5f).
4. Discussion
Morquio A syndrome (MPS IVA; MIM #253000) is an
autosomal recessive disorder caused by mutations in the
GALNS gene (NM 000512.4) located on chromosome
16q24.3 (Harmatz et al., 2013; Yasuda et al., 2013). To date
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Figure 2. Clinical features of Morquio A syndrome phenotypes observed in the families (A, B, C, D, E, F). Family A: Affected individual (VI-6)
showing pectus carinatum characterized by a protrusion of the sternum (a). Two affected individuals (IV-6, IV-7) displaying short stature (b).
Patient (IV-5) showing abnormal maxillary central incisors (c), joint laxity in forelimbs (d), genu valgum in legs (e). X-ray of dorso-lumbar
spine in lateral view of affected individual (IV-5) showing kyphosis with multilevel vertebra plana, central anterior beaking and broadening
of the anterior portion of the ribs (f). AP radiograph of the chest, arms, and pelvis of patient (IV-5) demonstrating distorted appearance of
ribs, irregular epiphysial plates, and anterior spiking of proximal ends of metaphysic accompanied by narrowed sciatic notch with flattening of
acetabulum roof (g). X-ray radiographs of chest, pelvis, and both femurs showing flared iliac bones laterally with inferior constriction (wineglass shape) (h). Enlargement of both acetabular cavities is seen with rough margins, and poorly designed femoral epiphyses and broadened
femoral necks with coxa valga. X-ray of leg/foot (lateral view) and knee (AP view) of patient (IV-5) showing tapering of the proximal phalanges
and genu valgus and metaphyseal expansion of long bones (i). Family B: Two affected members (IV-4, IV-5) demonstrating abnormal dentation
particularly that of maxillary central incisors (j, l). Three affected members in the family B (IV-4, IV-5, IV-6) showing disproportionate short
stature, and an unaffected individual (IV-3). An affected individual (IV-6) showing pectus carinatum (m). Family C: Affected individuals (IV-2,
IV-3) in family demonstrating genu valgum, abnormal maxillary central incisors, kyphoscolosis, and pectus carinatum (n–p). Family D: An
affected individual (IV-1) showing condition of genu valgus (q). Family E: Affected individuals (IV-2, IV-2) showing short stature, prognathism
(facial dysmorphology), dental anomalies, and corneal clouding (r). Family F: Affected member (IV-2) showing severe skeletal dysplasia,
craniofacial abnormalities, and corneal opacity (s). Family G: An affected female (IV-3) in family G showing short stature, prognathism, corneal
clouding, and wide-spaced teeth (t).
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Figure 3. Sequence analysis of the four novel and two reported mutations in the eight families. A missense mutation (c.
C1259 > G; p.Pro420Arg) identified in the gene GALNS in two families A and B (a–c). A missense mutation (c.1156C > T;
p.Arg386Cys) in family C (d–f). A novel mutation (c.T647 > C; p.Phe216Ser) in family D (g–i). A novel mutation (c.360–
361InsA; p. Glu121Argfs*37) in families E, F, and G (j–l). Novel heterozygous mutations, (c.114T > G; p.Met38Arg) and (c.871G
> T; p.Ala291Ser) in family H (m–r). The upper panels (a, d, g, j, m, p) represent the nucleotide sequences in affected, the middle
panels (b, e, h, k, n, q) in unaffected, and the lower panels in heterozygous carriers (c, f, i, l, r).

more than 200 mutations have been reported in GALNS
(Morrone et al., 2014a, 2014b; Stenson et al., 2014) and
this heterogeneity in the mutation spectrum is responsible
for clinical variability in Morquio A patients (Tomatsu
et al., 2005). Depending upon the nature and position of
the mutation, the structure and function of the protein is
altered to different extents, resulting in variable clinical
outcomes (Gnad et al., 2013).
In the present study, eight Pakistani consanguineous
families with Marqiuo A syndrome (MPS IV A) were
evaluated at clinical and molecular levels. Linkage was
established in seven families to the GALNS gene on
chromosome 16q24.3. Sequence analysis of the gene
revealed two previously reported missense mutations:
p.Pro420Arg in families A and B (Morrone et al., 2014a)
and p.Arg386Cys in family C (Tomatsu et al., 2004). In
addition, two novel mutations were identified: a missense
mutation (p.Phe216Ser) in family D and a frameshift
mutation (p.Glu121Argfs*37) in families E, F, and G.
TruSight One Sequencing Panel analysis in family
H, which failed to show linkage, detected a compound
heterozygous mutation in affected individuals. Sanger
sequencing confirmed that affected members of the family
carried two novel mutant alleles including p.Met38Arg
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inherited from their mother and p.Ala291Ser from their
father. Most likely, the occurrence of two heterozygous
mutations, c.[114T > G; 871G > T], supports the escape
from linkage in family H.
Online prediction tools such as Polyphen2, SIFT,
and Mutation Taster, indicated that missense mutations
discovered in this study probably have damaging effects on
the protein. Further in silico modeling of normal GALNS
protein and its mutants revealed that, according to the
nature and position of mutation, these substitutions altered
the intermolecular interactions within the protein, hence
distorting the normal structure to a variable extent. The
missense mutation (p.Pro420Arg), detected in families A
and B, disturbed surface residues in domain 2 of the GALNS
protein, affecting intermolecular contacts for correct
protein functioning (Rivera-Colón et al., 2012). The second
mutation (p.Arg386Cys), reported in family C, resulted in
disruption of the hydrophobic core of the GALNS protein.
The third missense mutation (p.Phe216Ser), detected in
family D, occurs in the N-terminal domain of GALNS,
affecting the glycosylation site of the protein. Alteration in
the glycosylation site of the GALNS protein may affect the
normal folding and endosome/lysosome trafficking of the
protein (Wujek et al., 2004; Pohl et al., 2009). Frameshift
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Table 2. Panel of genes with reference to the relevant diseases expected for pathogenic mutations in family H.
Gene symbol
IDUA

OMIM
252800

Disease

MIM

Mucopolysaccharidosis Ih

607014

Mucopolysaccharidosis Ih/s

607015

Mucopolysaccharidosis Is

607016

IDS

300823

Mucopolysaccharidosis II

309900

SGSH

605270

Mucopolysaccharidisis type IIIA (Sanfilippo A)

252900

NAGLU

609701

Mucopolysaccharidosis type IIIB (Sanfilippo B)

252920

HGSNAT

610453

Mucopolysaccharidosis type IIIC (Sanfilippo C)

252930

GNS

607664

Mucopolysaccharidosis type IIID

252940

GALNS

612222

Mucopolysaccharidosis IVA

253000

GLB1

611458

Mucopolysaccharidosis type IVB (Morquio)

253010

ARSB

611542

Mucopolysaccharidosis type VI (Maroteaux-Lamy)

253200

GUSB

611499

Mucopolysaccharidosis VII

253220

HYAL1

607071

Mucopolysaccharidosis type IX

601492

Cardiomyopathy, dilated, 1C, with or without LVNC

601493

Cardiomyopathy, hypertrophic, 24

601493

Left ventricular noncompaction 3

601493

Myopathy, myofibrillar, 4

609452

Muscular dystrophy, limb-girdle, type 1A

159000

Myopathy, myofibrillar, 3

609200

LDB3

605906

MYOT

604103

Myopathy, spheroid body

182920

HSPG2

142461

Schwartz–Jampel syndrome, type 1

255800

RPS6KA3

300075

Coffin–Lowry syndrome

303600

FBN1

134797

Marfan syndrome

154700

CREBBP

600140

Rubinstein–Taybi syndrome

180849

EP300

602700

Rubinstein–Taybi syndrome 2

613684

mutation (p.Glu121Argfs*37), identified in three families,
resulted in protein truncation with a premature stop codon
37 amino acids after frameshift. Compound heterozygous
missense mutations in family H (p.Met38Arg and
Ala291Ser) occur near the primary active site residues
(Asp39, Asp40, Asp288, and Asn289) (Rivera-Colón et al.,
2012), most likely affecting the conformation of the active
site and its substrate binding ability.
The difference between potential energy of the wildtype and mutant protein is a measure of the effect of
mutation on protein stability (Khan and Vihinen, 2010;
Zhang et al., 2010, 2012). Our results demonstrated that
missense mutations (p.Pro420Arg, p.Ala291Ser, and
p.Phe216Ser) resulted in the formation of additional
intramolecular interactions. Eventually, an increase in PE
was observed that may affect protein flexibility. In contrast,
a decrease in PE occurred in the case of two missense
mutations (p.Met38Arg and p.Arg386Cys) due to the loss

of intramolecular interactions (Table 1). Protein stability is
a key feature of protein function, and a missense mutation
may affect, besides the secondary structure, its stability,
leading to misfolding (Dobson, 2003; Koukouritaki et al.,
2007; Zhang et al., 2012). In fact, protein folding involves
fine-tuning of the linear unfolded polypeptide into the
native 3D structure driven by the potential energy gradient
(Ye et al., 2006; Dill et al., 2007). Recent studies revealed
that 80% of pathogenic missense mutations are amino
acid substitutions that affect the stability of proteins by
several kcal/mol (Wang and Moult, 2001). In addition, the
missense mutation can also alter protein flexibility (Young
et al., 2001; Karplus and Kuriyan, 2005; Zhang et al., 2010).
Generally, small energy values point toward a less stable
protein and vice versa.
Using GalNAc-6S as a ligand, molecular docking
analysis of normal and mutant GALNS protein revealed
that normal protein had a strong binding affinity (lower

465

ULLAH et al. / Turk J Biol

Figure 4. In silico structural modeling of GALNS mutations. The cartoon diagram of the entire GALNS protein comprehending
N-terminal domain (D1) containing the active site in magenta and central domain (D2) with antiparallel β-strands in cyan, followed
by followed by a C-terminal domain (D3) meander in yellow. The variants are featured in sphere models (A). Model structure of
GALNS showing the effect of mutations on intermolecular interactions. Upper row indicates intermolecular interaction of the normal
protein (a, c, e, g, i), while the lower row presents intermolecular interactions in the case of Pro420Arg (b), Arg386Cys (d), Phe216Ser
(f), Met38Arg (h), and Ala291Ser (j) mutants. The residues are symbolized in ball and stick models with a black dotted line displaying
the interactions.

docking score) than its mutant counterparts (high docking
score). Inconsistencies in binding affinities of mutated
proteins are a sign of geometrical constrains and/or
energetic effects caused by missense mutations (Akhavan
et al., 2005; Jones et al., 2007).
In conclusion, eight consanguineous families with
Morquio A syndrome were evaluated at clinical and
molecular level. Genetic analysis revealed six mutations
in the families including four novel (three missense and
one frameshift) and two previously reported mutations.
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In seven families the mutations occurred in homozygous
state while in one family compound heterozygous
mutations were identified causing severe phenotypes of
variable degree. Further, in silico analysis revealed that
these mutations alter the 3D structure, stability, and
binding affinity of the protein. Phenotypic variability in
the eight families was attributed to the deteriorations in
GALNS caused by mutations. For instance, frameshift
mutation resulted in the most severe phenotypes in three
families, which included intellectual disability and facial

ULLAH et al. / Turk J Biol

Figure 5. Predicated three-dimensional docking pose of 6S-GalNAc ligand in the active site of wild (a), Pro420Arg (b), Arg386Cys
(c), Phe216Ser (d), Met38Arg (e), and Ala291Ser (f) mutant types of human GALNS protein.

dysmorphology. Moreover, these results suggest that
in silico analysis is an effective approach to elucidate
the impact of missense mutations on the structure and
function of the protein and their ultimate influence on
phenotypes.
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